	US 12,187,801 B2
	Chimeric antigen receptors against AXL or ROR2 and methods of use thereof
Gregory Ian Frost, West Palm Beach, FL (US); James Joseph Onuffer, Jr., Alameda, CA (US); Jay M. Short, Jackson, WY (US); Gerhard Frey, San Diego, CA (US); and Hwai Wen Chang, San Marcos, CA (US)
Assigned to Exuma Biotech Corp., West Palm Beach, FL (US); and BioAtla. Inc., San Diego, CA (US)
Appl. No. 16/478,360
Filed by Exuma Biotech Corp., West Palm Beach, FL (US); and BioAtla. Inc., San Diego, CA (US)
PCT Filed Jan. 17, 2018, PCT No. PCT/US2018/014122 § 371(c)(1), (2) Date Jul. 16, 2019, PCT Pub. No. WO2018/136570, PCT Pub. Date Jul. 26, 2018.
Claims priority of provisional application 62/447,898, filed on Jan. 18, 2017.
Claims priority of provisional application 62/467,059, filed on Mar. 3, 2017.
Claims priority of provisional application 62/530,193, filed on Jul. 8, 2017.
Prior Publication US 2019/0367621 A1, Dec. 5, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/71 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01)

CPC C07K 16/2863 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464402 (2023.05); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 14/71 (2013.01); C07K 16/2803 (2013.01); C12N 5/0636 (2013.01); C12N 5/0646 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/59 (2023.05); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2319/03 (2013.01)]

22 Claims

1. A nucleic acid encoding a chimeric antigen receptor for binding Axl, comprising:

a) an antigen-specific targeting region (ASTR), wherein the ASTR binding to Axl comprises a heavy chain variable region comprising three complementarity determining regions having H1, H2, and H3 sequences and a light chain variable region comprising three complementarity determining regions having L1, L2, and L3 sequences, wherein:

i) the H1 sequence is X1GX2TMN (SEQ ID NO:87);

ii) the H2 sequence is LIKPSNGGTSYNQKFKG (SEQ ID NO:88);

iii) the H3 sequence is GX3YX4SYX5AMDY (SEQ ID NO:89);

iv) the L1 sequence is KASQDVX6SAVA (SEQ ID NO:90);

v) the L2 sequence is WX7X8TRX9T (SEQ ID NO:91); and

vi) the L3 sequence is QEHFSX10PLX11 (SEQ ID NO:92),

wherein X1 is T or W; X2 is Hor A; X3 is Hor D; X4 is E or H; X5 is E or F; X6 is S or V; X7 is A or Q; X8 is S or D; X9 is Hor D; X10 is T or P; and X11 is T or R;

b) a transmembrane domain; and

c) an intracellular activating domain, wherein the transmembrane domain is located between the ASTR and the intracellular activating domain.